FoundationOne MRD
Tissue-informed ctDNA MRD assay for stage II-III breast cancer using tumor WGS and multiplex dPCR.
- Developer
- Foundation Medicine
- Intended use
- Mrd
- Cancer scope
- Breast cancer
- Specimen
- FFPE tumor tissue, Peripheral whole blood
- Molecular modality
- DNA mutation
- Current version
- FoundationOne MRD launch/current configuration (2026)
- Evidence context
- 1 structured studies · 2 indexed performance results · 2 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.